中国实用医药
中國實用醫藥
중국실용의약
CHINA PRACTICAL MEDICAL
2009年
19期
80-81
,共2页
呼吸机相关性肺炎(VAP)%机械通气(MV)%病原菌%敏感药物
呼吸機相關性肺炎(VAP)%機械通氣(MV)%病原菌%敏感藥物
호흡궤상관성폐염(VAP)%궤계통기(MV)%병원균%민감약물
Ventilator-associated pneumonia%pathogenic bacteria%mechanical ventilation (MV)%Sensitive drug
目的 分析呼吸机相关性肺炎(VAP)的病原菌及其耐药性,为临床诊断与治疗提供参考依据.方法 对86例确诊为VAP患者的痰及下呼吸道分泌物进行细菌培养和药物敏感试验.结果 VAP患者占同期施行机械通气(MV)的27.2%;86例VAP患者中68例为混合感染,单一细菌感染者18例,共培养细菌202株,G-菌63.9%(铜绿假单胞菌61株(30.2%);鲍氏不动杆菌21株(10.4%),肺炎克雷伯菌12株(5.9%);G+菌23.8%(耐甲氧西林金黄色葡萄球菌(MRsA)36株(17.8),耐甲氧西林凝固酶阴性葡萄球菌(MRCNS)9株(4.5%));真菌12.3%(假丝酵母菌属18株(8.9%));耐药监测结果 显示G-菌均出现较强的耐药性.结论 临床医生应了解当地的流行菌株及其耐药性,合理选择、切忌滥用抗菌药物,以免造成耐药菌株的选择性生长或造成二重感染.
目的 分析呼吸機相關性肺炎(VAP)的病原菌及其耐藥性,為臨床診斷與治療提供參攷依據.方法 對86例確診為VAP患者的痰及下呼吸道分泌物進行細菌培養和藥物敏感試驗.結果 VAP患者佔同期施行機械通氣(MV)的27.2%;86例VAP患者中68例為混閤感染,單一細菌感染者18例,共培養細菌202株,G-菌63.9%(銅綠假單胞菌61株(30.2%);鮑氏不動桿菌21株(10.4%),肺炎剋雷伯菌12株(5.9%);G+菌23.8%(耐甲氧西林金黃色葡萄毬菌(MRsA)36株(17.8),耐甲氧西林凝固酶陰性葡萄毬菌(MRCNS)9株(4.5%));真菌12.3%(假絲酵母菌屬18株(8.9%));耐藥鑑測結果 顯示G-菌均齣現較彊的耐藥性.結論 臨床醫生應瞭解噹地的流行菌株及其耐藥性,閤理選擇、切忌濫用抗菌藥物,以免造成耐藥菌株的選擇性生長或造成二重感染.
목적 분석호흡궤상관성폐염(VAP)적병원균급기내약성,위림상진단여치료제공삼고의거.방법 대86례학진위VAP환자적담급하호흡도분비물진행세균배양화약물민감시험.결과 VAP환자점동기시행궤계통기(MV)적27.2%;86례VAP환자중68례위혼합감염,단일세균감염자18례,공배양세균202주,G-균63.9%(동록가단포균61주(30.2%);포씨불동간균21주(10.4%),폐염극뢰백균12주(5.9%);G+균23.8%(내갑양서림금황색포도구균(MRsA)36주(17.8),내갑양서림응고매음성포도구균(MRCNS)9주(4.5%));진균12.3%(가사효모균속18주(8.9%));내약감측결과 현시G-균균출현교강적내약성.결론 림상의생응료해당지적류행균주급기내약성,합리선택、절기람용항균약물,이면조성내약균주적선택성생장혹조성이중감염.
Objective Analyze ventilator-associated pneumonia's (VAP) pathogenic bacteria and drug resistance. Provide reference for clinical diagnosis and therapy. Method 86 cases who had diagnosed for VAP were collected the phlegm and lower respiratory tract secretions for bacterial culture and drug sensitivity test. Result VAP patients were accounted for the same period in patients with mechanical ventilation (MV) of 27.2%;in 86 cases of VAP patients, 68 cases were combined infection, 18 cases were single bacterial infection, A total of 202 bacteria for culture, G-bacteria 63.9% (Pseudomonas aeruginosa 61 (30.2));Acinetobacter baumannii 21 (10.4%), Klebsiella pneumoniae 12 (5.9%);G+ bacteria 23.8% (Methicillin-resistant Staphylococcus aureus (MRsA) 36 strain (17.8)), Methicillin-resistant coagulase-negative staphylococci (MRCNS) 9 strain (4.5%);eumycete 12.3% (Candida mycoderma 18 strain (8.9%));Resistance monitoring results indicated that G-bacteria were found strong resistance. Conclusion clinician should understand the prevalence of local strains and drug resistance, reasonably select, ovoid the abuse of antibiotics, In order to avoid drug-resistant strains caused by the selective growth or double infection.
